.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Novartis
Julphar
Merck
Argus Health
Boehringer Ingelheim
Cantor Fitzgerald
Queensland Health
Healthtrust

Generated: December 16, 2017

DrugPatentWatch Database Preview

Concordia Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for CONCORDIA PHARMS INC, and what generic alternatives to CONCORDIA PHARMS INC drugs are available?

CONCORDIA PHARMS INC has twelve approved drugs.

There are two US patents protecting CONCORDIA PHARMS INC drugs.

There are sixty patent family members on CONCORDIA PHARMS INC drugs in thirty-eight countries and thirty-seven supplementary protection certificates in nine countries.

Summary for Concordia Pharms Inc

International Patents:60
US Patents:2
Tradenames:13
Ingredients:11
NDAs:12
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia Pharms IncDUTOPROLhydrochlorothiazide; metoprolol succinateTABLET, EXTENDED RELEASE;ORAL021956-003Aug 28, 2006RXYesYes► Subscribe► Subscribe► Subscribe
Concordia Pharms IncJENLOGAclonidine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022331-001Sep 30, 2009DISCNYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms IncDUTOPROLhydrochlorothiazide; metoprolol succinateTABLET, EXTENDED RELEASE;ORAL021956-002Aug 28, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms IncDUTOPROLhydrochlorothiazide; metoprolol succinateTABLET, EXTENDED RELEASE;ORAL021956-001Aug 28, 2006RXYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms IncJENLOGAclonidine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022331-002May 25, 2010DISCNYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms IncORAPREDprednisolone sodium phosphateSOLUTION;ORAL075117-001Dec 14, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe
Concordia Pharms IncDYRENIUMtriamtereneCAPSULE;ORAL013174-001Approved Prior to Jan 1, 1982RXYesNo► Subscribe► Subscribe► Subscribe
Concordia Pharms IncKAPVAYclonidine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022331-003Sep 28, 2010AB1RXYesYes► Subscribe► Subscribe► Subscribe
Concordia Pharms IncDYRENIUMtriamtereneCAPSULE;ORAL013174-002Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Concordia Pharms IncLANOXINdigoxinTABLET;ORAL020405-001Sep 30, 1997RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Concordia Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms IncORAPRED ODTprednisolone sodium phosphateTABLET, ORALLY DISINTEGRATING;ORAL021959-002Jun 1, 2006► Subscribe► Subscribe
Concordia Pharms IncJENLOGAclonidine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022331-001Sep 30, 2009► Subscribe► Subscribe
Concordia Pharms IncORAPRED ODTprednisolone sodium phosphateTABLET, ORALLY DISINTEGRATING;ORAL021959-003Jun 1, 2006► Subscribe► Subscribe
Concordia Pharms IncORAPRED ODTprednisolone sodium phosphateTABLET, ORALLY DISINTEGRATING;ORAL021959-001Jun 1, 2006► Subscribe► Subscribe
Concordia Pharms IncKAPVAYclonidine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022331-004Sep 28, 2010► Subscribe► Subscribe
Concordia Pharms IncUROXATRALalfuzosin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021287-001Jun 12, 2003► Subscribe► Subscribe
Concordia Pharms IncKAPVAYclonidine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022331-003Sep 28, 2010► Subscribe► Subscribe
Concordia Pharms IncJENLOGAclonidine hydrochlorideTABLET, EXTENDED RELEASE;ORAL022331-002May 25, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CONCORDIA PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
clonidine hydrochlorideExtended-release Tablets0.1 mg and 0.2 mgKAPVAY3/4/2011
clonidine hydrochlorideExtended-release Tablets0.1 mg and 0.2 mgJENLOGA3/4/2011
prednisolone sodium phosphateOrally Disintegrating Tablets10 mg, 15 mg and 30 mgORAPRED7/22/2010
alfuzosin hydrochlorideExtended-release Tablets10 mgUROXATRAL6/12/2007

International Patent Family for Concordia Pharms Inc Drugs

Country Document Number Estimated Expiration
Israel128146► Subscribe
European Patent Office0938318► Subscribe
Russian Federation2183459► Subscribe
Spain2159400► Subscribe
China100335057► Subscribe
Hungary228007► Subscribe
Hong Kong1146901► Subscribe
Estonia03855► Subscribe
Taiwan522023► Subscribe
Greece3036291► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Concordia Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C0108Belgium► SubscribePRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
C/GB97/078United Kingdom► SubscribePRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
C/GB08/036United Kingdom► SubscribePRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
595Luxembourg► SubscribePRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Baxter
Cantor Fitzgerald
Express Scripts
Chubb
Queensland Health
Citi
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot